Nancy Blas Velez, MD
General Practice · Zephyrhills, FLNPI 1629134952
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AstraZeneca at 28.5% of the total. Reporting peaked in 2022 at $172 and has fallen 60.0% since, to $69 in 2025.
Across 20 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$96
- GSK$83
- Lilly USA, LLC$56
- Boehringer Ingelheim$46
- Boston Scientific$20
- Exact Sciences$19
- plus $18 from 1 others
What the payments were for
- Food & beverage$338100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $96 |
| GSK | 5 | $83 |
| Lilly USA, LLC | 3 | $56 |
| Boehringer Ingelheim | 2 | $46 |
| Boston Scientific | 1 | $20 |
| Exact Sciences | 1 | $19 |
| AbbVie | 1 | $18 |
How this compares
$338 in reported general payments places this provider in the 55th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 101 | $107,537 |
| EliquisApixaban | 53 | $70,440 |
| ForteoTeriparatide | 13 | $56,057 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $50,301 |
| JardianceEmpagliflozin | 56 | $49,128 |
| OzempicSemaglutide | 54 | $48,426 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $42,982 |
| XareltoRivaroxaban | 33 | $33,969 |
| JanuviaSitagliptin Phosphate | 25 | $30,570 |
| FarxigaDapagliflozin Propanediol | 28 | $27,206 |
| EntrestoSacubitril/Valsartan | 17 | $22,366 |
| MounjaroTirzepatide | 16 | $16,912 |
| Spiriva RespimatTiotropium Bromide | 12 | $8,532 |
| MyrbetriqMirabegron | 14 | $7,932 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $6,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Forteo, Mounjaro | $56 | $180,506130 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $46 | $57,66068 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $83 | $57,08287 claims |
| AstraZenecaFarxiga, Symbicort | $96 | $32,38447 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 6,901 general practice providers in Florida.
Other general practice in Zephyrhills
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
- Sarah JockinTampa$308K
- Mario RomeroSarasota$275K
- Robert RitterJupiter$233K
- Robert AltharPensacola$231K
- Florencia ZiemkeWest Palm Beach$208K
- Ausberto HidalgoPembroke Pines$171K
- Rickie FergusonPembroke Pines$170K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.